ReadyCell News
Stay up-to-date on the latest ReadyCell news, projects and developments.
Honoring 20 years of dedication from our team
This year, we had the privilege of celebrating 20 years of dedication from four of our esteemed colleagues—Sheila Guisado, Lourdes Gombau, Alberto Corcho, and Marta Corvo.
Recommended reference compounds for permeability assays
Permeability assays are important for understanding how molecules cross biological barriers, assessing both their ability to cross and the mechanisms involved. While drugs are often absorbed by passive diffusion, some molecules can also be substrates for membrane proteins or transporters.
Caco-2 Permeability Assay Protocol
The permeability assay protocol for Caco-2 cells serves as a cornerstone in understanding and predicting the intestinal absorption of pharmaceutical agents.
ReadyCell announces acquisition by MedTech Barcelona, a Leitat Company
We inform you that as of October 2024, Leitat, through its proprietary company MedTech Innovation...
Advancements in β-Glucocerebrosidase modulation: new therapeutics for Gaucher’s Disease
This research, titled Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β‑Glucocerebrosidase, highlights the potential of fragment-based drug discovery (FBDD) and employs permeability assays with CacoReady and PreadyPort plates.
ReadyCell presents the final reporting period of the SEGURAM project
The final presentation highlighted the potential of gut-on-a-chip technology to advance bioavailability and efficacy testing in the meat industry.
A successful presence at the BIO International Convention
We extend our sincere thanks to everyone who visited our booth #900. With over 200 visits, more than 20 meetings, and hundreds of valuable new contacts, we are thrilled to have connected with so many industry professionals.
Presenting the latest results of the BioprintIA project
The event united all the participating companies and partners, who presented the 2023 achievements and the challenges they faced to the project manager. Each presentation showcased the remarkable progress and collaboration, underscoring our shared dedication to innovation and problem-solving.
ReadyCell demonstrates new inflammation model at SLAS Europe 2024
The team presented the results of their study, in which they used CacoGoblet, a 21-day differentiated co-culture of human colon carcinoma cell lines (Caco-2 and HT-29), to screen the gastrointestinal anti-inflammatory properties of compounds.
ReadyCell presented its latest software implementation at the Exact Event in Barcelona
This software was specially designed to manage our customers’ orders, as well as to automate the management of documentation and quality controls, facilitating orders worldwide and speeding up the generation of the necessary documents for customs.
A pioneering investigation unveils novel allosteric inhibitors of SHP2 in cancer therapy
In a recent publication in the Journal of Medicinal Chemistry, a collaborative research led by the scientist Dr. H. Day, in conjunction with a consortium of researchers, explored the development of allosteric inhibitors targeting SH2 domain-containing protein tyrosine phosphatase-2 (SHP2) for cancer therapy.
ReadyCell at the Bio-Europe Spring 2024
ReadyCell is attending BIO-Europe Spring in Barcelona. The event is expected to bring together executives from biotech and pharma companies.
